This article explores the 20 stocks insiders were selling in Q1 2025. Previously, we covered the 20 stocks insiders were buying in Q1 2025.
The broader market index rose 0.2% on Tuesday amid volatility as investors awaited clarity on President Trump’s tariff policy. The market also faced pressure from weaker-than-expected economic data, including a disappointing manufacturing survey and lower-than-expected job openings, according to CNBC. The blue chip companies and Nasdaq Composite also saw modest gains, with the market continuing to react to uncertainty.
As this market uncertainty persists, insider trading often draws attention. While executive stock purchases can signal optimism, insider sales may stem from personal financial reasons or diversification needs. Executives typically follow pre-arranged plans, like 10b5-1, to ensure transparency. Insider trading offers insights but should be considered alongside a company’s financial health and market conditions.
A close-up of a trader’s hands executing a futures trade on a trading floor.
Our Methodology
What are some of the stocks that insiders have been selling the most in the first quarter of the year? To find out, we used Insider Monkey’s insider trading stock screener, focusing only on stocks where at least five insiders had sold shares in January, February, or March. From there, we ranked the 20 stocks with the highest number of insiders selling shares.
Today, we’re focusing on stocks that insiders have been heavily selling during the first three months of the year. Using Insider Monkey’s insider trading screener, we identified stocks where at least five insider sales totaled $1 million or more. While the overall value of insider sales for these stocks may be higher, we specifically focused on sales worth $1 million or more. From the stocks that met this criterion, we selected the 20 with the highest number of insider sales of $1 million or more.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
With each stock, we note the average price per share of these purchases and the stock’s market capitalization. Let’s take a look at the 20 stocks insiders were selling in Q1 2025.
20. Insmed Incorporated (NASDAQ:INSM)
Total value of insider sales in Q1: $53.02 million
Insiders with $1M+ sales: 6
Insmed Incorporated develops therapies for serious and rare diseases, with treatments like ARIKAYCE for lung infections and brensocatib for bronchiectasis in clinical trials. The Bridgewater, New Jersey-based company is also developing treatments for pulmonary hypertension and Duchenne muscular dystrophy. It is also one of the 12 most promising biotech stocks according to Wall Street analysts.
In February 2025, the FDA accepted the company’s New Drug Application (NDA) for brensocatib for patients with bronchiectasis and granted the application Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of August 12, 2025. Insmed continues to expect brensocatib will launch in the U.S. in the third quarter, if approved.
During the first quarter, seven insiders, including the CEO, COO, and CFO, sold approximately $53.02 million worth of Insmed shares at an average price of $73.79 per share. The stock now trades at $75.13 per share, having gained 8.82% year-to-date. Over the past 12 months, its shares returned 181.14%.
According to the 16 analysts Insmed stock is a “Buy,” with a price target of $94.00 per share, reports MarketBeat. The average price target suggests a potential upside of 25.05% from the latest price.
19. Intercontinental Exchange, Inc. (NYSE:ICE)
Total value of insider sales in Q1: $65.11 million
Insiders with $1M+ sales: 6
Intercontinental Exchange, Inc. provides technology and data services to financial institutions, corporations, and governments in various countries. It operates in three segments: Exchanges, Fixed Income and Data Services, and Mortgage Technology. The Georgia, Atlanta-based company offers marketplace technology for trading, pricing and analytics services, and a digital platform for U.S. residential mortgage market workflows.
For the fourth quarter of 2024, Intercontinental reported net income of $698 million on $2.3 billion in revenue, with GAAP EPS of $1.21 and adjusted EPS of $1.52. Revenue grew 6% year-over-year, driven by its exchange, fixed income, and mortgage tech businesses. For the year, the company generated $4.6 billion in operating cash flow, $3.6 billion in free cash flow, and paid over $1 billion in dividends, ending 2024 with $844 million in cash and $20.4 billion in debt.
During the first quarter, 11 insiders, including the COO, and CFO sold around $65.11 million worth of Intercontinental shares at an average price of $167.11 per share. Currently, the stock trades at $172.25 per share, having risen 15.60% year-to-date and 25.70% over the past 12 months.
Fourteen analysts rate Intercontinental stock as “Strong Buy” with a price target of $185.67 per share, according to TipRanks. The average price target represents a 7.78% upside from the latest price.
Intercontinental Exchange is also one of the 10 best financial stocks to buy according to billionaires.
